Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

HEALTHCARE (NY:XLV)

143.94 +0.66 (+0.46%)
Streaming Delayed Price Updated: 10:00 AM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about HEALTHCARE

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
39 40 Next >
Is It Time To Shift Focus To Beaten-Down Healthcare Stocks As Volatility Soars?
Healthcare performed terribly in 2023 and 2024, falling while the market was soaring. Year-to-date, the sector has outperformed. Is it time to focus on the stocks and ETFs of this low-Beta sector as... 
Via Talk Markets
Topics ETFs Stocks / Equities
Biotech Rally Coming In Weeks Ahead?
Large cap biopharma and MedTech stocks are leading the healthcare sector higher. 
Via Talk Markets
Topics ETFs Stocks / Equities
Leading And Lagging Sectors For March 4, 2025
 
Via Benzinga
Making Bets On The Money
The top-performing sector last week was financials, they closed up over 2.8% on the week at their highest weekly and monthly level in history. 
Via Talk Markets
Topics Stocks / Equities
Leading And Lagging Sectors For March 3, 2025
 
Via Benzinga
US Sector Leadership Shifts, Favoring Healthcare Stocks
Via Talk Markets
Topics ETFs
Leading And Lagging Sectors For February 28, 2025
 
Via Benzinga
Moderna Stock Heads For Weekly Loss As Retail Caution Prevails: Wealth Advisor Tells Why She's Staying On The Sidelines
The stock fell over 7% on Thursday after reports that federal health officials under the Trump administration are re-evaluating Moderna's $590 million contract for bird flu vaccine development. 
Via Stocktwits
Topics Government
Leading And Lagging Sectors For February 27, 2025
 
Via Benzinga
Leading And Lagging Sectors For February 26, 2025
 
Via Benzinga
Leading And Lagging Sectors For February 25, 2025
 
Via Benzinga
Biotech Stocks Stay Strong Through A Period Of Uncertainty In The Market
Many analysts are feeling better about the prospects for healthcare stocks in 2025. 
Via Talk Markets
Topics ETFs Stocks / Equities
Staples Surge On A Dime
We’re starting to see money flows into more defensive sectors of the market. This is rather concerning in the near-term. 
Via Talk Markets
Topics Stocks / Equities
Leading And Lagging Sectors For February 24, 2025
 
Via Benzinga
NIH Funding Cuts To Spook Healthcare Stocks? RFK Jr's Confirmation At HHS Sparks Concerns Over Research Dollars, 'Causing Uncertainty,' Says Analyst
Robert F. Kennedy Jr.'s appointment as Secretary of Health and Human Services has sparked concerns over funding for the NIH. 
Via Benzinga
Leading And Lagging Sectors For February 21, 2025
 
Via Benzinga
Leading And Lagging Sectors For February 20, 2025
 
Via Benzinga
Medtronic Logs Worst Day In Nearly 5 Years On Q3 Revenue Miss, But Retail Goes Bargain Hunting
The company said its medical-surgical segment struggled with ongoing stapling market pressures and temporary shifts in U.S. distributor buying patterns. 
Via Stocktwits
Biotech Stocks Had A Good Week Despite Crosscurrents
It’s too early to account for the rally but in general one can say that there is a lot of speculation from both the retail side and hedge funds. 
Via Talk Markets
Topics ETFs Stocks / Equities
Leading And Lagging Sectors For February 18, 2025
 
Via Benzinga
Health Insurance ETFs in Focus as RFK Jr Takes Over HHS
Robert F. Kennedy Jr. has taken office as HHS secretary, which could impact the healthcare sector, including ETFs with exposure to insurers like UnitedHealth and Elevance Health. 
Via Benzinga
Topics ETFs
Leading And Lagging Sectors For February 17, 2025
 
Via Benzinga
China, Gold, Momentum Lead, But Surprisingly Savvy Investors Turn Bearish
Momentum stocks are leading the market higher, but this is much different leadership than what elevated the market in 2024. 
Via Talk Markets
Topics ETFs Stocks / Equities
Moderna’s Q4 Losses Worse Than Feared, But Revenue Beat And Cost Cuts Boost Stock — Retail Sentiment Follows
CEO Stéphane Bancel said the company remains focused on driving sales and achieving up to 10 product approvals by 2027, as well as removing nearly $1 billion in costs by the end of this year. 
Via Stocktwits
CVS Showered With Upgrades, PT Hikes After Q4 Beat Powers Stock To Best Day In Over 25 Years: Retail Cheer Grows
Analysts largely believe that the company’s Aetna insurance business is set to rebound and its margins will recover soon. 
Via Stocktwits
Biogen Stock Slides To Fresh 12-Year Lows As Profit Outlook Misses, But Retail Snaps Up The Dip
The company's breakthrough Alzheimer's drug, Leqembi, generated $87 million in Q4 sales, well ahead of the $67 million analysts expected. 
Via Stocktwits
Gilead Wins Price-Target Boosts After Solid Q4, Retail Brushes Off Medicare Reform Hit To HIV Drugs
Investors seem encouraged by the company's strong performance in its core business areas and the promise of further growth driven by its expanding pipeline. 
Via Stocktwits
Leading And Lagging Sectors For February 12, 2025
 
Via Benzinga
Beginnings And Blends: S&P 500 Sector Performance In The New Year
No matter how vast the index landscape becomes, sectors remain central to the conversation. 
Via Talk Markets
Topics Stocks Stocks / Equities
Vertex Pharma Stock Flooded With Price-Target Hikes After Upbeat Q4 Revenue, 2025 Outlook: Retail Stays Bullish
The company is betting on strong sales of its cystic fibrosis drugs and early traction from its newly approved non-opioid painkiller. 
Via Stocktwits
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
39 40 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.